Abbott Laboratories Earnings Recaps
Q1 2026
Apr 16, 2026
Abbott delivered aligned first-quarter results with steady earnings and achieved a key strategic milestone with the acquisition of Exact Sciences, enhancing its diagnostics leadership and growth prospects.
Key takeaways
- Adjusted EPS of $1.15 met guidance despite headwinds from early financing costs and a weaker respiratory season.
- Completed the Exact Sciences acquisition, adding ~$3 billion in expected 2026 sales and accelerating long-term growth trajectory.
- Diagnostics sales grew 2%, with Core Lab up 3%, while Molecular Diagnostics declined 10% due to weaker respiratory testing demand.
- Cancer Diagnostics posted 13% growth driven by strong international performance and Cologuard.
- Medical Devices revenue increased 8.5%, led by robust cardiovascular product sales, supported by pipeline advancements and clinical trial initiatives.
Q3 2025
Oct 16, 2025
Abbott Laboratories reported a robust 7.5% organic sales growth in Q3 2025, primarily driven by a strong performance in medical devices and established pharmaceuticals, despite a decline in COVID test sales.
Key takeaways
- Earnings per share rose to $1.30, reflecting high single-digit growth year-over-year, excluding COVID test impacts.
- New product launches contributed nearly $5 billion in sales this quarter, adding over 100 basis points to organic sales growth.
- Medical Devices segment grew by 12.5%, led by solid performances in diabetes care and electrophysiology.
- Established Pharmaceuticals experienced high single-digit growth, driven by strong contributions from core markets and therapeutic areas.
- Strategic investments in nutrition products are set to leverage favorable consumer trends, evidenced by new launches in the adult nutrition segment.